Evidence map›Paper›PMID 41286664›Full record

ArticleBMC infectious diseases2025

SARS-CoV-2 reinfection in interstitial lung disease patients and its association with clinical deterioration: a two-year prospective cohort study.

Yuanying Wang, Dongmei Wang, Yawen Song, Na Wu, Xuqin Du, Qiao Ye

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuanying Wang *Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China.
Dongmei Wang *Clinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China.
Yawen SongClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China.
Na WuClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China.
Xuqin DuClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China.
Qiao YeClinical Center for Interstitial Lung Diseases, Beijing Institute of Respiratory Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Worker's Stadium No.8, Chao-Yang District, Beijing, 100020, China. yeqiao_chaoyang@sina.com.

Funding

High Level Public Health Technology Talent Construction Project DL-02-21Reform and Development Program of Beijing Institute of Respiratory Medicine Ggyfz202512
6 · The paper itself

Abstract

backgroundThe COVID-19 pandemic has raised concerns about respiratory sequelae, particularly in the patients with preexisting interstitial lung disease (ILD). This study aimed to evaluate the longitudinal impacts of SARS-CoV-2 reinfection on patients with preexisting ILD, focusing on differential outcomes between single and multiple infection episodes.

methodsA prospective cohort study was conducted (December 2022-March 2023), enrolling 347 adults with preexisting ILD and confirmed COVID-19 infection. Follow-up assessments were performed at baseline, 6-, 12-, and 24-month intervals. Data included demographics, pulmonary function tests (PFTs), high-resolution computed tomography (HRCT) scores, and clinical outcomes. Composite deterioration endpoint incorporating acute exacerbation (AE), decline in forced vital capacity (FVC), decline in diffusing capacity (D

resultsAmong 347 patients (82.13% single infection, 17.87% multiple infections), the multiple infection group exhibited significantly higher disease deterioration rates (61.29% vs. 41.75%, P = 0.005). Multivariable Cox analysis identified multiple infections (HR = 1.50, 95% CI 1.03-2.19), higher baseline fibrosis scores (HR = 1.64), respiratory failure (HR = 1.84), and COVID-19 pneumonia (HR = 1.58) as independent risk factors. Patients with multiple infections showed accelerated FVC% decline (P = 0.016). All-cause mortality did not differ significantly between groups (11.29% vs. 9.12%, P = 0.598). Subgroup analyses suggested broadly consistent risks across ILD subtypes.

conclusionRepeated SARS-CoV-2 infections may be associated with disease deterioration in patients with preexisting lung fibrosis. CLINICAL TRIAL NUMBER: Not applicable.

Indexed as

COVID-19Lung Diseases, InterstitialReinfectionAdultAgedClinical DeteriorationDisease ProgressionFemaleHumansMaleMiddle AgedProspective StudiesRespiratory Function TestsSARS-CoV-2Tomography, X-Ray ComputedCOVID-19Idiopathic pulmonary fibrosisInterstitial lung diseasePrognosis

Identifiers

PMID41286664
PMCPMC12642266

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.